bms-986172
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2021 (NCT04926051)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 2-acylglycerol O-acyltransferase 2INHIBITOR
MOGAT2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1N[C@@](c2ccc(OCCCC(F)(F)F)cc2F)(C(F)(F)F)CC(c2ccn(CC3CC3)n2)=C1n1nn[nH]c1=O- Mol. weight
- 589.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5418882 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04926051 | Phase 1 | Jun 15, 2021 | Bristol-Myers Squibb |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1